非布司他治疗痛风并高脂血症的疗效分析(1)
[摘要] 目的 分析非布司他治療痛风合并高脂血症的临床疗效及血脂水平、血尿酸情况影响。方法 简单随机选择2016年1月—2019年6月福建省级机关医院风湿血液科80例痛风合并高脂血症非住院患者，随机数字编号分组：对照组与研究组，其中，对照组给予别嘌醇治疗，研究组给予非布司他治疗。对组间的治疗前后血尿酸水平、血脂水平(TG、TC、HDL-C、LDL-C)、临床治疗总有效率、不良反应发生率(肝肾功能异常率、皮肤瘙痒率)进行指标对比。结果 就研究组而言，其治疗后血尿酸水平(352.22±100.12)μmol/L、血脂水平中TG(1.76±1.11)mmol/L、TC(4.41±1.11) mmol/L、LDL-C(2.66±0.44) mmol/L指标均低于对照组，差异有统计学意义(t=2.050、5.320、2.030、3.700，P<0.05)，且其临床治疗总有效率(97.50%)、血脂水平中HDL-C(1.24±0.33) mmol/L指标均高于对照组，差异有统计学意义(χ2=5.000，t=2.200，P<0.05);研究组与对照组之间的治疗前血尿酸水平与血脂水平(TG、TC、HDL-C、LDL-C)、不良反应发生率(肝肾功能异常率、皮肤瘙痒率)指标差异无统计学意义(t=0.000、0.030、0.140、0.200、0.160，χ2=0.160，P>0.05)。结论 非布司他治疗痛风合并高脂血症患者，可以提高其临床治疗效果，改善患者的血脂与血尿酸水平，且治疗安全性突出。
[关键词] 非布司他;痛风合并高脂血症;临床疗效;血脂水平;血尿酸;安全性
[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742(2020)09(a)-0073-03
[Abstract] Objective To analyze the clinical efficacy of febuxostat in the treatment of gout with hyperlipidemia and the effect of blood lipid levels and blood uric acid. Methods Eighty non-hospitalized patients with gout and hyperlipidemia in the Department of Rheumatology and Hematology of Fujian Provincial Government Hospital were ramdom selected from January 2016 to June 2019. random number grouping： control group and study group， among them， the control group was given allopurinol treatment， and the study group was given febuxostat treatment. Index comparison of blood uric acid levels， blood lipid levels (TG， TC， HDL-C， LDL-C)， clinical treatment total effective rate， and adverse reaction rate (abnormal liver and kidney function rate， skin itching rate) between two groups before and after treatment. Results As far as the study group is concerned， blood uric acid level (352.22±100.12)μmol/L， blood lipid level in TG (1.76±1.11)mmol/L， TC (4.41±1.11)mmol/L， LDL-C (2.66 ±0.44) mmol/L indicators were lower than those of the control group， the difference was statistically significant (t=2.050， 5.320， 2.030， 3.700，P<0.05)， and its clinical treatment total effective rate (97.50%)， blood lipid level HDL-C(1.24±0.33) mmol/L indicators were all higher than the control group， the difference was statistically significant(χ2=5.000，t=2.200，P<0.05); the blood uric acid level and blood lipid level (TG， TC， HDL-C， LDL-C)， the incidence of adverse reactions (abnormal liver and kidney function rate， skin pruritus rate) index differences are not statistically significant (t=0.000，0.030，0.140，0.200，0.160，χ2=0.160，P>0.05). Conclusion Febuxostat in the treatment of patients with gout and hyperlipidemia can improve the clinical therapeutic effect， improve the blood lipids and blood uric acid levels of the patients， and has outstanding treatment safety., 百拇医药(高一丹)
[关键词] 非布司他;痛风合并高脂血症;临床疗效;血脂水平;血尿酸;安全性
[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742(2020)09(a)-0073-03
[Abstract] Objective To analyze the clinical efficacy of febuxostat in the treatment of gout with hyperlipidemia and the effect of blood lipid levels and blood uric acid. Methods Eighty non-hospitalized patients with gout and hyperlipidemia in the Department of Rheumatology and Hematology of Fujian Provincial Government Hospital were ramdom selected from January 2016 to June 2019. random number grouping： control group and study group， among them， the control group was given allopurinol treatment， and the study group was given febuxostat treatment. Index comparison of blood uric acid levels， blood lipid levels (TG， TC， HDL-C， LDL-C)， clinical treatment total effective rate， and adverse reaction rate (abnormal liver and kidney function rate， skin itching rate) between two groups before and after treatment. Results As far as the study group is concerned， blood uric acid level (352.22±100.12)μmol/L， blood lipid level in TG (1.76±1.11)mmol/L， TC (4.41±1.11)mmol/L， LDL-C (2.66 ±0.44) mmol/L indicators were lower than those of the control group， the difference was statistically significant (t=2.050， 5.320， 2.030， 3.700，P<0.05)， and its clinical treatment total effective rate (97.50%)， blood lipid level HDL-C(1.24±0.33) mmol/L indicators were all higher than the control group， the difference was statistically significant(χ2=5.000，t=2.200，P<0.05); the blood uric acid level and blood lipid level (TG， TC， HDL-C， LDL-C)， the incidence of adverse reactions (abnormal liver and kidney function rate， skin pruritus rate) index differences are not statistically significant (t=0.000，0.030，0.140，0.200，0.160，χ2=0.160，P>0.05). Conclusion Febuxostat in the treatment of patients with gout and hyperlipidemia can improve the clinical therapeutic effect， improve the blood lipids and blood uric acid levels of the patients， and has outstanding treatment safety., 百拇医药(高一丹)